Canadian urology research gains momentum

2013 CUA Astellas grant recipients announced 
MARKHAM, ON, Aug. 29, 2013 /CNW/ - The Canadian Urological Association (CUA) 
and Astellas Pharma Canada, Inc. are proud to partner for a second year in 
support of the CUA Astellas Research Grant Program. 
Last year, Astellas pledged $750,000 over a period of five years to support 
Canadian peer-reviewed urology research and promote excellence in urological 
research. The ultimate goal of the grant program is to improve patient care. 
With a detailed application review process based on a defined set of criteria, 
this year Dr. Rendon invited Dr. Alan So, a prominent CUA member from 
Vancouver, to co-chair the Scientific Council. Together, they shared the 
duties of the review process and oversaw the review committee. 
The CUA Astellas Research Grant is beginning to gain both prominence and 
momentum within the urology research community, resulting in 19 applications 
for the 2013 competition. We are pleased to announce the 2013 recipients, who 
Dr. Kourosh Afshar University of British Columbia, Vancouver, BC
Project Title: Voiding disorders and autonomic NS activity in children 
Dr. Sumit Dave University of Western Ontario, London, ON
Project Title: A clinical trial to determine the extent to which probiotic 
therapy reduces side effects of antibiotic prophylaxis in pediatric neurogenic 
bladder patients with a history of recurrent urinary tract infections 
Dr. Alp Sener University of Western Ontario, London, ON
Project title: Novel delivery method of supplemental hydrogen sulphide and 
caspace-3 siRNA during mechanical perfusion are protective in a donation after 
cardiac death model of porcine renal transplantation 
"This innovative research can lead to important discoveries that may 
ultimately change the treatment landscape for patients with urological 
conditions," says Michael Tremblay, President, Astellas Pharma Canada, Inc. 
"It is tremendously exciting for us to support the work of these doctors 
because their research has the potential to improve quality of life for 
Canadian patients." 
About the Canadian Urological Association (CUA)
The CUA Mission is to represent and provide a voice for all Canadian 
urologists and to foster dedication of all members of the profession toward 
ensuring the highest possible standard of urologic care for Canadians. 
The goals of the CUA are to: 

    --  To foster and promote excellence in urologic practice through
        education and research.
    --  To provide leadership in promoting evidence based clinical
        practice through the development of practice guidelines.
    --  To foster and promote life-long learning by Canadian urologists
        through continuous professional development.
    --  To provide leadership in public education for urologic
    --  To represent Canadian urology in developing and fostering
        partnerships while maintaining the highest educational and
        ethical standards.
    --  To represent the Canadian urologic community in relationships
        with national and international medical societies.

More information about CUA can be found at

About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian 
affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical 
company dedicated to improving the health of people around the world through 
the provision of innovative and reliable pharmaceutical products.

The organization is committed to becoming a global category leader in focused 
areas by combining outstanding R&D and marketing capabilities. In Canada, 
Astellas has an intense commercial focus on five therapeutic areas - Urology, 
Immunology, Infectious Disease, Dermatology and Oncology.

For more information about Astellas Pharma Canada, Inc., please visit the 
corporate website:

SOURCE  Astellas Pharma Canada, Inc. 
 Tiffany Pizioli Executive Director, CUA Office of Education Canadian 
Urological Association (514) 395-0376 ext. 44 
Naomi Côté Corporate Communications Astellas Pharma Canada, Inc. (905) 
To view this news release in HTML formatting, please use the following URL: 
CO: Astellas Pharma Canada, Inc.
ST: Ontario
-0- Aug/29/2013 12:30 GMT
Press spacebar to pause and continue. Press esc to stop.